ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Mergers & Acquisitions

Lilly acquires AurKa

by Ryan Cross
May 21, 2018 | APPEARED IN VOLUME 96, ISSUE 21

 

Eli Lilly & Co. is expanding its cancer drug pipeline by buying back a compound it sold to TVM Capital Life Science in 2016. TVM founded AurKa Pharma to develop the compound, AK-01, and AurKa is now testing it in several solid tumors in Phase I clinical trials. Lilly will pay $110 million for AurKa plus up to $465 million in milestone payments. AK-01 inhibits a protein called Aurora kinase A, which plays a role in controlling cell division. Too much of the protein can promote cancer.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment